Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors

NGM Biopharmaceuticals

09/01/2024 14:24

Jan 9 (Reuters) - NGM Biopharmaceuticals Inc  NGM.O :
    * NGM BIO ANNOUNCES NEW CLINICAL DATA FROM ONGOING TRIAL OF
NGM707
IN ADVANCED SOLID TUMORS AND OUTLINES EVOLVED STRATEGY FOR
ALDAFERMIN AND NGM120 TO FOCUS ON RARE CONDITIONS WITH
SIGNIFICANT UNMET NEED
    * NGM BIOPHARMACEUTICALS INC - COMBINATION OF NGM707 AND
PEMBROLIZUMAB WAS GENERALLY WELL TOLERATED AT ALL FOUR DOSE
LEVELS OF NGM707
    * NGM BIOPHARMACEUTICALS INC - COMPLETING ENROLLMENT IN
PHASE 1
PART 1B COHORT AND ANTICIPATES PROVIDING AN UPDATE IN MID-2024
ON COMPLETED COHORT
    * NGM BIOPHARMACEUTICALS INC - ALDAFERMIN DEMONSTRATED BOTH
STATISTICALLY SIGNIFICANT IMPROVEMENTS IN BIOMARKERS OF HEPATIC
INJURY AND FIBROSIS
    * NGM BIOPHARMACEUTICALS INC -  ALDAFERMIN DEMONSTRATED
STATISTICALLY SIGNIFICANT REDUCTIONS IN BIOMARKERS OF BILE ACID
SYNTHESIS AND SERUM BILE ACIDS
    * NGM BIOPHARMACEUTICALS INC -  PHASE 2 STUDY OF ALDAFERMIN
MET
SECONDARY ENDPOINTS AND WAS GENERALLY WELL TOLERATED BY PATIENTS
    * NGM BIOPHARMACEUTICALS INC - PLAN TO INITIATE A
REPRODUCTIVE
TOXICOLOGY STUDY OF NGM120 FOR TREATMENT OF HYPEREMESIS IN 2024
    * NGM BIOPHARMACEUTICALS INC - CONTINUE EXPLORING PARTNERING
OPPORTUNITIES ACROSS FULL NGM BIO PRODUCT CANDIDATE AND RESEARCH
PORTFOLIO

Source text for Eikon:  ID:nGNXRSFFV 
Further company coverage:  NGM.O 

 (Reuters.Briefs@thomsonreuters.com)